Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular ...
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by ...
CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.